A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The hypothesis of the study is that at least one dose of CP 690 550 is superior to placebo
(inactive drug) in inducing remission in patients with moderate to severe ulcerative colitis.